Voyager Therapeutics
64 Sidney Street
Cambridge
Massachusetts
02139
United States
Website: http://www.voyagertherapeutics.com/
175 articles about Voyager Therapeutics
-
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 22, 2022
9/22/2022
Voyager Therapeutics, Inc. has entered into employment agreements with Peter Pfreundschuh and another newly hired employee that, among other things, provide for the grant to such employees of non-qualified stock options and restricted stock units as inducements material to such employees’ entering into employment with Voyager.
-
Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.
-
Voyager Therapeutics Appoints Peter Pfreundschuh as CFO; Todd Carter, Ph.D., as Chief Scientific Officer; and Trista Morrison as SVP Corporate Affairs
9/7/2022
Voyager Therapeutics, Inc. announced the appointment of Peter Pfreundschuh as Chief Financial Officer ; Todd Carter, Ph.D., as Chief Scientific Officer ; and Trista Morrison as Senior Vice President of Corporate Affairs.
-
Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
8/4/2022
Voyager Therapeutics, Inc., a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus capsids, unveiled its prioritized therapeutic pipeline and reported second quarter 2022 financial and operating results.
-
Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models
8/3/2022
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today presented data showing the use of novel antibodies targeting hyperphosphorylated forms of tau.
-
Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update
8/2/2022
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022.
-
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to its Board of Directors
7/28/2022
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors.
-
The 25th Annual Meeting of the American Society of Gene and Cell Therapy wrapped up on Thursday. BioSpace looks at some of the highlights.
-
Voyager Therapeutics’ TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy Programs
5/19/2022
Voyager Therapeutics, Inc. is scheduled to present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system transduction.
-
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
-
Voyager Therapeutics to Present Preclinical Data from its Vectorized anti-HER2 Antibody Program and a Novel AAV5-Derived TRACER™ Capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting
5/16/2022
Voyager Therapeutics, Inc. is scheduled to present findings demonstrating preclinical proof-of-concept for its vectorized anti-HER2 antibody program and cross-species translatability for its novel AAV5-derived capsid at the 25th American Society of Gene and Cell Therapy Annual Meeting.
-
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
-
Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results
5/4/2022
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, reported first quarter 2022 financial and operating results.
-
Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting
5/3/2022
Voyager Therapeutics, Inc. today announced nine data presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19 in Washington, D.C.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
3/22/2022
Voyager Therapeutics, Inc. today announced the appointment of Alfred W. Sandrock, Jr., M.D., Ph.D., as chief executive officer (CEO).
-
Less than two months after joining the executive committee of the Voyager Therapeutics Board of Directors, Alfred W. Sandrock Jr. has been named CEO of the company.
-
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
3/8/2022
Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, reported fourth quarter and full year 2021 financial and operating results.
-
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
3/8/2022
Voyager Therapeutics, Inc. announced an agreement through which Novartis may exercise options to license novel AAV capsids generated from Voyager’s RNA-driven TRACERTM capsid discovery platform for potential use with three undisclosed CNS targets and options to access capsids for two additional targets to be agreed on in the future.
-
Voyager has partnered with Novartis for the latter to use the gene therapy company's capsid discovery platform to create new treatments for three undisclosed CNS targets.